Atossa Genetics Reports Results From "Expanded Access" Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability Issues

Stock Information for Atossa Genetics Inc.

Loading

Please wait while we load your information from QuoteMedia.